Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

The major workforce overhaul comes a month after parent company Roche deemed the cell and gene therapy firm a financial loss.

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price target ...